Britain's health watchdog NICE is opening up free access to a group of aromatase inhibitors for postmenopausal women with invasive hormone-receptor-positive breast cancer. The decision will allow for free access to such drugs as AstraZeneca's Arimidex and Novartis' Femara. Article